European Medicines Agency starts review of VIR-7831 for treating patients with COVID-19

Agency is reviewing currently data on use of this monoclonal antibody, including data from a study in patients with mild to moderate COVID-19 showing that VIR-7831 reduced the risk of hospitalisation for more than 24 hours or death by 85% vs. placebo.

Source:

European Medicines Agency